In a groundbreaking exploration of neuroimmunology intersecting with oncology, researchers have unveiled a remarkable mechanism by which ectopic expression of NMDA receptors (NMDARs) in cancer cells unlocks previously enigmatic germline-encoded autoimmunity. This discovery illuminates the profound structural intricacies of NMDAR modulation by tumour-derived antibodies and their consequential influence on receptor conformation and function, offering fresh vistas into autoimmune pathogenesis and cancer therapy.
At the heart of this investigation lies the detailed examination of NMDAR conformational states, specifically focusing on the allosteric transitions critical to receptor activation. The functional repertoire of NMDARs encompasses a dynamic equilibrium between multiple closed-channel states: a non-active configuration characterized by a more relaxed conformation, and a pre-active or primed state distinguished by a compact assembly of the amino-terminal domain (ATD) and ligand-binding domain (LBD). Transitioning between these states involves subtle yet crucial conformational rearrangements, including a reduction in inter-residue distances such as those between GluN2B Arg184 and GluN1 Lys178 in the ATD interface (termed α4′–α5), and GluN2B Leu425 and GluN1 Arg489 in the LBD (L1′–L2), which fundamentally underpin channel gating.
Harnessing advanced cryo-electron microscopy (cryo-EM), the researchers delved into the structural consequences of tumour-derived autoantibody binding to GluN1–GluN2B heteromeric NMDAR complexes. Their analyses uncovered a novel, previously uncharacterized receptor conformation termed “pre-active2.” This state was distinguished by an asymmetric conformational rearrangement in one of the two GluN1–GluN2B ATD heterodimers, marked notably by a reduction in the α4′–α5 distance exclusive to the ATD-1 dimer without accompanying shortening in the LBD’s L1′–L2 distances. The pre-active2 conformation also features an approximate 14° opening of the GluN2B ATD clamshell across both ATD-1 and ATD-2, a modification intimately linked to intersubunit ATD rearrangement and suggestive of a transitional intermediate bridging open and non-active states.
Further investigations into antibody affinity maturation revealed that antibodies matured through the SK3D lineage primarily stabilized this pre-active2 conformation, contrasting with the minor and partial stabilization seen in SK5A-matured populations. Interestingly, the presence of a second antibody molecule binding to a distinct ATD-2 site appeared to fortify the pre-active2 state, indicating a cooperative mechanism enhancing receptor modulation. Importantly, germline SK3D antibodies demonstrated a considerably lower prevalence of this state, underscoring the pivotal role of affinity maturation in leveraging antibody-induced receptor structural transitions.
The studies extended to interrogate the agonist dependence of antibody binding, employing SK5A-matured antibodies complexed with GluN1–GluN2B receptors in the absence of traditional agonists glycine and glutamate. The structural fidelity of the antibody-receptor interface between agonist-bound and apo states confirmed that antibody engagement is independent of receptor functional state. Intriguingly, the antibody-bound apo conformation resembled the glycine-bound gly/apo state and retained glycine within the GluN1 LBD clamshell, a reflection of glycine’s physiological persistence in synaptic environments, unlike glutamate’s tightly regulated extracellular concentrations.
Through meticulous analysis of α4′–α5 inter-residue distances across a suite of antibody-NMDAR complexes, the research identified discrete conformational states—gly/apo, pre-active, open, pre-active2, and non-active—each correlating with varying functional outcomes. Across all complexes, the ion channel remained predominantly in a closed state, evidenced by absent gating features such as outward tension within the GluN2B LBD–M3′ linker and interdomain rotations between the LBD and the transmembrane domain. This structural insight was corroborated through refined model fitting to localized regions of the receptor, affirming the utility of α4′–α5 distance as a reliable conformational metric.
Functional assays using two-electrode voltage clamp (TEVC) recordings in Xenopus laevis oocytes expressing recombinant GluN1–GluN2B receptors elucidated the physiological repercussions of diverse autoantibody binding. SK3D- and SK5A-matured antibodies robustly potentiated NMDAR currents in a dose-dependent manner, achieving current enhancements exceeding 200% at nanomolar concentrations. Conversely, SK5G-matured antibodies induced a dose-dependent inhibition of receptor activity, while SK5B-matured antibodies exhibited minimal modulatory effects. Control antibodies lacking receptor binding (mGO53) demonstrated no influence on ionic currents, solidifying the specificity of antibody-mediated functional modulation.
The team extended these findings into tumour biology contexts, hypothesizing that potentiating antibodies might induce excitotoxicity in NMDAR-expressing cancer cells, while inhibitory antibodies might confer protective effects. Cytotoxicity assays affirmed this conjecture: SK3D antibodies elicited dose-dependent cell death with an IC50 near 120 nM, whereas SK5G antibodies did not significantly impair cell viability. These findings translated in vivo, where administration of SK3D mIgG2a antibodies to 4T1-NMDAR tumour-bearing B-cell-deficient mice significantly enhanced tumour regression upon doxycycline-induced tumour antigen expression. Remarkably, some treated tumours exhibited near-complete pathological remission, characterized by minimal pan-cytokeratin-positive cells and heightened immune transcript signatures, implicating both direct cytotoxicity and immune activation in therapeutic efficacy.
Collectively, this research delineates a sophisticated spectrum of autoantibody effects on NMDARs, from potent inhibition to minimal or substantial potentiation of channel currents. The precise conformational states induced by different antibodies, particularly the pivotal α4′–α5 distance as a structural correlate, enable predictive modeling of functional outcomes. This correlation not only deepens understanding of antibody-mediated receptor modulation but also provides a structural basis for therapeutic targeting in diseases where ectopic NMDAR expression and autoantibody interactions are pathogenic.
Beyond revealing nuanced structural transitions, these findings carry transformative implications for autoimmune and cancer therapeutics. The identification of tumor-derived antibodies able to modulate NMDAR function opens novel avenues for precision immunotherapy, leveraging autoantibody-induced excitotoxicity in malignancies expressing neuronal receptors. Moreover, the elucidation of antibody binding dynamics independent of receptor agonist states informs strategies for antibody design and intervention development.
Intriguingly, this study pushes the frontier of autoimmunity research by demonstrating that germline-encoded autoantibodies, when directed toward ectopically expressed neural antigens in tumors, can manifest diverse functional phenotypes with direct consequences for disease progression and treatment response. The application of cryo-EM in resolving these complexes at high resolution signifies a leap forward in structurally guided immunological investigations, fostering the integration of structural biology and immunotherapy.
As the field progresses, the framework established here may catalyze detailed explorations into the conformational plasticity of other ligand-gated ion channels targeted by autoantibodies. The intricate dance of receptor domains revealed in the pre-active2 conformation emphasizes the complexity inherent in autoantibody-receptor interactions and the necessity of high-resolution, dynamic structural characterization for holistic understanding.
This seminal study, recently published in Nature by Kleeman et al., harnesses state-of-the-art structural techniques and electrophysiological approaches to unravel the interplay between tumor-derived autoantibodies and NMDA receptor function. The insights garnered not only illuminate mechanisms of cancer-associated autoimmunity but also lay the groundwork for rational development of antibodies as precision oncology agents capable of manipulating neural receptor pathways for therapeutic benefit.
Subject of Research: The study investigates the ectopic expression of NMDA receptors in cancer and its role in unmasking germline-encoded autoimmunity through tumour-derived antibodies that modulate receptor conformation and function.
Article Title: Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity.
Article References:
Kleeman, S.O., Michalski, K., Zhao, X. et al. Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity. Nature (2026). https://doi.org/10.1038/s41586-026-10278-0
DOI: https://doi.org/10.1038/s41586-026-10278-0
